{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:39:08Z","timestamp":1783330748283,"version":"3.54.6"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001635","name":"University of Limerick","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001635","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017413","name":"Innovation Fund","doi-asserted-by":"publisher","award":["DT\/2018\/0054"],"award-info":[{"award-number":["DT\/2018\/0054"]}],"id":[{"id":"10.13039\/100017413","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.cyto.2025.156994","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T17:49:51Z","timestamp":1752601791000},"page":"156994","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Therapeutic potential of an immunomodulatory enzyme, ScpA, in interferon gamma (IFN-\u03b3) induced skin psoriasis"],"prefix":"10.1016","volume":"194","author":[{"given":"Promita","family":"Bhattacharjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinayakumar","family":"Gedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratik kumar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah P.","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran","family":"McGourty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2025.156994_bb0005","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/S0140-6736(03)12954-6","volume":"361","author":"Lebwohl","year":"2003","journal-title":"Psoriasis. Lancet"},{"key":"10.1016\/j.cyto.2025.156994_bb0010","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nature05663","article-title":"Pathogenesis and therapy of psoriasis","volume":"445","author":"Lowes","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.cyto.2025.156994_bb0015","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jaad.2006.08.040","article-title":"Prevalence of cardiovascular risk factors in patients with psoriasis","volume":"55","author":"Neimann","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.cyto.2025.156994_bb0020","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1365-2133.2010.09941.x","article-title":"Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K","volume":"163","author":"Abuabara","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.cyto.2025.156994_bb0025","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/ced.12841","article-title":"Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA","volume":"41","author":"Korman","year":"2016","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.cyto.2025.156994_bb0030","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.it.2004.03.006","article-title":"Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and \u2018type 10 inflammatory gene expression","volume":"25","author":"Lew","year":"2004","journal-title":"Trends Immunol."},{"key":"10.1016\/j.cyto.2025.156994_bb0035","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1046\/j.1523-1747.1999.00749.x","volume":"113","author":"Austin","year":"1999","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.cyto.2025.156994_bb0040","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/ni1254","article-title":"Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages","volume":"6","author":"Harrington","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cyto.2025.156994_bb0045","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1084\/jem.20070663","article-title":"Phenotypic and functional features of human Th17 cells","volume":"204","author":"Annunziato","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cyto.2025.156994_bb0050","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1172\/JCI37865","article-title":"Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD\/SCID recipient mice","volume":"119","author":"Bending","year":"2009","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.cyto.2025.156994_bb0055","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3892\/ijmm.2015.2433","article-title":"IL-17 intensifies IFN-\u03b3-induced NOS2 upregulation in RAW 264.7 cells by further activating STAT1 and NF-\u03baB","volume":"37","author":"Gao","year":"2016","journal-title":"Int. J. Mol. Med."},{"issue":"5","key":"10.1016\/j.cyto.2025.156994_bb0060","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.febslet.2005.01.009","article-title":"In silico identification of the key components and steps in IFN-\u03b3 induced JAK-STAT signaling pathway","volume":"579","author":"Zi","year":"2005","journal-title":"FEBS Lett."},{"issue":"12","key":"10.1016\/j.cyto.2025.156994_bb0065","first-page":"28","article-title":"New and emerging topical therapies for psoriasis and atopic dermatitis","volume":"12","author":"Psomadakis","year":"2019","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"10.1016\/j.cyto.2025.156994_bb0070","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.754116","article-title":"A scoping review on use of drugs targeting the JAK\/STAT pathway in psoriasis","volume":"9","author":"G\u00f3mez-Garc\u00eda","year":"2022","journal-title":"Front. Med."},{"issue":"4","key":"10.1016\/j.cyto.2025.156994_bb0075","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.cyto.2025.156994_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2024.156652","article-title":"C5a peptidase (ScpA) activity towards human type II and type III interferons","volume":"180","author":"Duarte","year":"2024","journal-title":"Cytokine"},{"key":"10.1016\/j.cyto.2025.156994_bb0085","first-page":"351","article-title":"Psoriasis induced at the injection site of recombinant interferon gamma","volume":"126","author":"Fierlbeck","year":"1990","journal-title":"Results of immunohistologic investigations. Arch Dermatol"},{"issue":"4","key":"10.1016\/j.cyto.2025.156994_bb0090","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/jid.2011.458","article-title":"A single intradermal injection of IFN-\u03b3 induces an inflammatory state in both non-lesional psoriatic and healthy skin","volume":"132","author":"Johnson-Huang","year":"2012","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.cyto.2025.156994_bb0095","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/art.1780400110","article-title":"A randomized, double-blind study comparing twenty-four-week treatment with recombinant interferongamma versus placebo in the treatment of rheumatoid arthritis","volume":"40","author":"Veys","year":"1997","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cyto.2025.156994_bb0100","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.crbiot.2021.05.006","article-title":"Microbial therapeutic enzymes: a promising area of biopharmaceuticals","volume":"3","author":"Vachher","year":"2021","journal-title":"Current Research in Biotechnology"},{"issue":"5","key":"10.1016\/j.cyto.2025.156994_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.104685","article-title":"Antibody-guided proteases enable selective and catalytic degradation of challenging therapeutic targets","volume":"299","author":"Romei","year":"2023","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.cyto.2025.156994_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J. Biomed. Sci."},{"issue":"1","key":"10.1016\/j.cyto.2025.156994_bb0115","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41392-022-01056-1","article-title":"Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.cyto.2025.156994_bb0120","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3390\/biom12020306","article-title":"An introduction to bacterial biofilms and their proteases, and their roles in host infection and immune evasion","volume":"12","author":"Ram\u00edrez-Larrota","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.cyto.2025.156994_bb0125","doi-asserted-by":"crossref","first-page":"8144","DOI":"10.1073\/pnas.82.23.8144","article-title":"Mechanism of action of the group a streptococcal C5a inactivator","volume":"82","author":"Wexler","year":"1985","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"10.1016\/j.cyto.2025.156994_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006493","article-title":"Multi-functional mechanisms of immune evasion by the streptococcal complement inhibitor C5a peptidase","volume":"13","author":"Lynskey","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.cyto.2025.156994_bb0135","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1016\/j.csbj.2021.04.024","article-title":"Enzyme kinetic and binding studies identify determinants of specificity for the immunomodulatory enzyme ScpA, a C5a inactivating bacterial protease","volume":"19","author":"Te\u00e7za","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"8","key":"10.1016\/j.cyto.2025.156994_bb0140","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1021\/acs.molpharmaceut.3c00207","article-title":"Impact of Propeptide cleavage on the stability and activity of a streptococcal immunomodulatory C5a peptidase for biopharmaceutical development","volume":"20","author":"Gedi","year":"2023","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.cyto.2025.156994_bb0145","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0190-9622(99)70358-0","article-title":"Retinoids and psoriasis: novel issues in retinoid pharmacology and implications for psoriasis treatment","volume":"41","author":"Saurat","year":"1999","journal-title":"J. Am. Acad. Dermatol."},{"issue":"5","key":"10.1016\/j.cyto.2025.156994_bb0150","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1365-2133.1972.tb16108.x","article-title":"Retinoic acid in the treatment of psoriasis","volume":"86","author":"Macdonald","year":"1972","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.cyto.2025.156994_bb0155","doi-asserted-by":"crossref","first-page":"11838","DOI":"10.1038\/s41598-017-12041-y","article-title":"Immortalized N\/TERT keratinocytes as an alternative cell source in 3D human epidermal models","volume":"7","author":"Smits","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.cyto.2025.156994_bb0160","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/2211068214561025","article-title":"TEER measurement techniques for in vitro barrier model systems","volume":"20","author":"Srinivasan","year":"2015","journal-title":"J. Lab. Autom."},{"key":"10.1016\/j.cyto.2025.156994_bb0165","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0887-2333(02)00084-X","article-title":"Rapid integrity assessment of rat and human epidermal membranes for in vitro dermal regulatory testing: correlation of electrical resistance with tritiated water permeability","volume":"16","author":"Fasano","year":"2002","journal-title":"Toxicol. in Vitro"},{"issue":"1","key":"10.1016\/j.cyto.2025.156994_bb0170","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/1523-1747.ep12391802","article-title":"Up-regulation of elafin\/SKALP gene expression in psoriatic epidermis","volume":"103","author":"Nonomura","year":"1994","journal-title":"J. Invest. Dermatol."},{"issue":"4","key":"10.1016\/j.cyto.2025.156994_bb0175","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/1523-1747.ep12484041","article-title":"Molecular cloning, occurrence, and expression of a novel partially secreted protein \u201cpsoriasin\u201d that is highly up-regulated in psoriatic skin","volume":"97","author":"Madsen","year":"1991","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.cyto.2025.156994_bb0180","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1177\/1535370217710637","article-title":"In vitro psoriasis models with focus on reconstructed skin models as promising tools in psoriasis research","volume":"242","author":"Desmet","year":"2017","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.cyto.2025.156994_bb0185","series-title":"Skin Tissue Models","first-page":"103","article-title":"In vitro models of psoriasis","author":"Roy","year":"2018"},{"key":"10.1016\/j.cyto.2025.156994_bb0190","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaut.2015.07.008","article-title":"The immunogenetics of psoriasis: a comprehensive review","volume":"64","author":"Harden","year":"2015","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.cyto.2025.156994_bb0195","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.3389\/fimmu.2018.01549","article-title":"The interplay between keratinocytes and immune cells in the pathogenesis of psoriasis","volume":"9","author":"Albanesi","year":"2018","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.cyto.2025.156994_bb0200","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jaci.2015.03.051","article-title":"The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling","volume":"136","author":"Amano","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"issue":"5","key":"10.1016\/j.cyto.2025.156994_bb0205","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/jid.2013.503","article-title":"In vitro assessment of IL-4-or IL-13-mediated changes in the structural components of keratinocytes in mice and humans","volume":"134","author":"Omori-Miyake","year":"2014","journal-title":"J. Invest. Dermatol."},{"issue":"2S","key":"10.1016\/j.cyto.2025.156994_bb0210","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.12788\/j.sder.2018.010","article-title":"Treating to target\u2014a realistic goal in psoriasis","volume":"37","author":"Gordon","year":"2018","journal-title":"Semin. Cutan. Med. Surg."},{"key":"10.1016\/j.cyto.2025.156994_bb0215","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s13555-020-00409-4","article-title":"Long-term safety of oral systemic therapies for psoriasis: a comprehensive review of the literature","volume":"10","author":"Balak","year":"2020","journal-title":"Dermatol. Ther."},{"issue":"2","key":"10.1016\/j.cyto.2025.156994_bb0220","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jaci.2014.05.046","article-title":"Humanized anti\u2013IFN-\u03b3 (HuZAF) in the treatment of psoriasis","volume":"135","author":"Harden","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"issue":"5","key":"10.1016\/j.cyto.2025.156994_bb0225","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/j.0022-202X.2005.23691.x","article-title":"The book of opposites: the role of the nuclear receptor co-regulators in the suppression of epidermal genes by retinoic acid and thyroid hormone receptors","volume":"124","author":"Jho","year":"2005","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.cyto.2025.156994_bb0230","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.3389\/fimmu.2019.01866","article-title":"C5a\/C5aR1 pathway is critical for the pathogenesis of psoriasis","volume":"10","author":"Zheng","year":"2019","journal-title":"Front. Immunol."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466625001413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466625001413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T20:32:50Z","timestamp":1755808370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466625001413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":46,"alternative-id":["S1043466625001413"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2025.156994","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic potential of an immunomodulatory enzyme, ScpA, in interferon gamma (IFN-\u03b3) induced skin psoriasis","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2025.156994","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"156994"}}